Trial Profile
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA or EPZICOM/KIVEXA, in Treatment-Naive HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Doravirine (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms DRIVE-FORWARD
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 26 Oct 2022 Results (of three phase 3 studies DRIVE-FORWARD, DRIVE- AHEAD and DRIVE-SHIFT) assessing Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen presented at the 16th International Congress on Drug Therapy and HIV Infection